Evaluation of tolerance and toxicity of high-dose-rate brachytherapy boost combined with interstitial hyperthermia for prostate cancer

References

• National Institutes of Health Consensus Development. Consensus statement: the management of clinically localized prostate cancer. NCI Monogr 1988;7:3–6.
   PubMedGoogle Scholar
• Fowler FJ, Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance epidemiology and end results areas. J Clin Oncol 1996;14:2258–65.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Prostate Cancer, version 2.2014. NCCN; 2014. Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed 7 October2014).
   Google Scholar
• Hoskin PJ, Colombo A, Henry A, Niehoff P, Paulsen Hellebust T, Siebert FA, et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol 2013;107:325–32.
   PubMed Web of Science ®Google Scholar
• Skowronek J. Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer – between options. J Contemp Brachytherapy 2013;5:33–41.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Rogers L, Demanes DJ, Morton G, Prestidge BR, Pouliot J, et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 2012;11:20–32.
   PubMed Web of Science ®Google Scholar
• Zaorsky NG, Doyle LA, Yamoah K, Andrel JA, Trabulsi EJ, Hurwitz MD, et al. High dose rate brachytherapy boost for prostate cancer: a systematic review. Cancer Treat Rev 2014;40:414–25.
   PubMed Web of Science ®Google Scholar
• Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M, III, Jung AJ, Carroll PR, et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 2012;82:e787–93.
   PubMed Web of Science ®Google Scholar
• Peschke P, Hahn EW, Wolber G, Hildenbrand D, Zuna I. Interstitial radiation and hyperthermia in the Dunning R3327 prostate tumour model: therapeutic efficacy depends on radiation dose-rate, sequence and frequency of heating. Int J Radiat Biol 1996;70:609–16.
   PubMed Web of Science ®Google Scholar
• Ryu S, Brown SL, Kim SH, Khil MS, Kim JH. Preferential radiosensitization of human prostatic carcinoma cells by mild hyperthermia. Int J Radiat Oncol Biol Phys 1996;34:133–8.
   PubMed Web of Science ®Google Scholar
• Tilly W, Gellermann J, Graf R, Hildebrandt B, Weissbach L, Budach V et al. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0. Strahlenther Onkol 2005;181:35–41.
   PubMed Web of Science ®Google Scholar
• Van Vulpen M, De Leeuw AA, Raaymakers BW, Van Moorselaar RJ, Hofman P, Lagendijk JJ, et al. Radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate cancer: preliminary results. BJU Int 2004;93:36–41.
   PubMed Web of Science ®Google Scholar
• Maluta S, Dall’Oglio S, Romano M, Marciai N, Pioli F, Giri MG, et al. Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study. Int J Hyperthermia 2007;23:451–6.
   PubMed Web of Science ®Google Scholar
• Pajonk F, Van Ophoven A, Mc Bride WH. Hyperthermia induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Res 2005;65:4836–43.
   PubMed Web of Science ®Google Scholar
• Kalapurakal JA, Pierce M, Chen A, Sathiaseelan V. Efficacy of irradiation and external hyperthermia in locally advanced, hormone-refractory or radiation recurrent prostate cancer: a preliminary report. Int J Radiat Oncol Biol Phys 2003;57:654–64.
   PubMed Web of Science ®Google Scholar
• Hurwitz MD, Hansen JL, Prokopios-Davos S, Manola J, Wang Q, Bornstein BA, et al. Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 94-153. Cancer 2011;117:510–16.
   PubMed Web of Science ®Google Scholar
• Kukiełka AM, Hetnał M, Brandys P, Walasek T, Dąbrowski T, Pluta E, et al. Interstitial hyperthermia of the prostate in combination with brachytherapy: an evaluation of feasibility and early tolerance. Strahlenther Onkol 2013;189:467–75.
   PubMed Web of Science ®Google Scholar
• Kukiełka AM, Hetnał M, Dąbrowski T, Walasek T, Brandys P, Nahajowski D, et al. Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure. Strahlenther Onkol 2014;190:165–70.
   PubMed Web of Science ®Google Scholar
• Prionas SD, Kapp DS, Goffinet DR, Ben-Yosef R, Fessenden P, Bagshaw MA. Thermometry of interstitial hyperthermia given as an adjuvant to brachytherapy for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1994;28:151–62.
   PubMed Web of Science ®Google Scholar
• Van Vulpen M, De Leeuw JR, Van Gellekom MP, Van Der Hoeven J, De Graeff A, Van Moorselaar RJ, et al. A prospective quality of life study in patients with locally advanced prostate cancer treated with radiotherapy with or without regional or interstitial hyperthermia. Int J Hyperthermia 2003;19:402–13.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Potter R, Loch T, Hammer J, Kolkman-Deurloo IK, de la Rosette JJ, et al. GEC-ESTRO EAU recommendations on temporary brachytherapy using stepping sources for localized prostate cancer. Radiother Oncol 2005;74:137–48.
   PubMed Web of Science ®Google Scholar
• Chung HT, Speight JL, Roach M. Intermediate- and high-risk prostate cancer. In: Halperin EC, Perez CA, Brady LW, (eds). Principles and practice of radiation oncology, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2008 pp. 1483–504.
   Google Scholar
• Emami B, Stauffer P, Dewhirst MW, Prionas S, Ryan T, Corry P, et al. RTOG quality assurance guidelines for interstitial hyperthermia. Int J Radiat Oncol Biol Phys 1991;20:1117–24.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
   Google Scholar
• Demanes DJ, Ghilezan MI. High-dose-rate brachytherapy as monotherapy for prostate cancer. Brachytherapy 2014;13:529–41.
   PubMed Web of Science ®Google Scholar
• Chen CP, Weinberg V, Shinohara K, Roach M, III, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 2013;86:324–9.
   PubMed Web of Science ®Google Scholar
• Ataman F, Zurlo A, Artignan X, van Tienhoven G, Blank LE, Warde P, et al. Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer 2004;40:1674–81.
   PubMed Web of Science ®Google Scholar
• Gawkowska-Suwińska M, Fijałkowski M, Białas B, Szlag M, Kellas-Ślęczka S, Nowicka E, et al. Salvage brachytherapy for local recurrences of prostate treated previously with radiotherapy. J Contemp Brachyther 2009;1:211–15.
   Google Scholar
• Łyczek J, Kawczyńska MM, Garmol M, Kasprowicz A, Kulik A, Dąbkowski M, et al. HDR brachytherapy as a solution in recurrences of locally advanced prostate cancer. J Contemp Brachyther 2009;1:105–8.
   PubMedGoogle Scholar
• Nguyen PL, D’Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 2007;110:1417–27.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124–9.
   PubMed Web of Science ®Google Scholar
• Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002;54:1063–8.
   PubMed Web of Science ®Google Scholar
• Duchesne GM, Williams SG, Das R, Tai KH. Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results. Radiother Oncol 2007;84:128–34.
   PubMed Web of Science ®Google Scholar
• Hsu IC, Bae K, Shinohara K, Pouliot J, Purdy J, Ibbott G, et al. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys 2010;78:751–8.
   PubMed Web of Science ®Google Scholar
• Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 2010;33:481–8.
   PubMed Web of Science ®Google Scholar
• Morton GC. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol (R Coll Radiol) 2005;17:219–27.
   PubMed Web of Science ®Google Scholar
• Pellizzon AC, Salvajoli JV, Maia MA, Ferrigno R, Novaes PE, Fogarolli RC, et al. Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer. J Urol 2004;171:1105–8.
   PubMed Web of Science ®Google Scholar